DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More
myocardial infarction
DIGAMI 2 Trial: Insulin-Based Glucose Control in Type 2 Diabetic Patients Following MI
DIGAMI 2 Trial Summary Introduction:The DIGAMI 2 trial aimed to evaluate the effect of insulin-based glucose control in type 2 diabetic patients following myocardial infarction compared to conventional management at similar levels of glucose control. The study investigated three treatment … Read More
BRIGHT-4 Trial Summary: Bivalirudin in STEMI
2022 BRIGHT-4 TRIAL Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with STEMI undergoing primary PCI investigator-initiated, open-label, randomized controlled trial Objective: To evaluate the safety and efficacy of a high-dose infusion of bivalirudin after primary percutaneous coronary … Read More
TRANSFER AMI Trial Summary: Early Angioplasty after Fibrinolysis for Acute MI
2009 TRANSFER-AMI trial: Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction Multicenter, randomized, non-blinded, parallel Assignment Objective: To assess outcomes in patients with AMI treated with thrombolysis transferring to a center providing PCI for standard treatment (rescue PCI or … Read More
PARADISE MI Trial Summary: Sacubitril-valsartan vs ramipril in acute MI
2021 PARADISE-MI M Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction international, multicenter, randomized, double-blind, active-comparator trial S S 1. Objective: To compare the effects of sacubitril-valsartan and angiotensin converting-enzyme inhibitor, ramipril in patients with acute myocardial infarction 5661 Inclusion criteria: … Read More